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The transcriptome profiles of the cingulate gyrus region from the postmortem brain 
tissues of a set of well-characterized patients with schizophrenia (SCZ) and matched 
controls were investigated using an integrated approach that analyzed both the 
alterations in transcription expression pattern and rare genetic variants in expressed 
genes. We demonstrated increased expression of astrocyte-related genes using 
spatiotemporal co-expression modules that have previously been established for 
developing human brain, and showed these results are independent of medication 
dosage. The relationship between genetic variants and expression pattern in the 
context of neurodevelopment was further investigated, and we identified an enrichment 
of rare genetic variants in a set of signature genes that were specific to astrocytes and 
up-regulated in the patients with SCZ. Our result suggested the involvement of 
astrocyte malfunction in SCZ pathophysiology. In addition, our approach indicated a 
novel strategy of narrowing down genetic variants that might contribute to the 
pathophysiology in the patients with SCZ to a subset of genes that are highly 
expressed in an affected brain region. 
 
INTRODUCTION 
Schizophrenia (SCZ) is a complex disease, affecting 1% of the population with 
devastating consequences for sufferers, their families and public health. Rare genetic 
variants with high penetrance, such as single nucleotide variants (SNVs), small 
insertions/deletions (indels) and even larger copy-number variants (CNVs) have been 
shown to be collectively enriched in SCZ susceptibility by recent human genetic 
studies (Kirov et al., 2012; Purcell et al., 2014; Rees et al., 2013; Xu et al., 2008; Xu 
et al., 2012). However, the contribution of individual variants to the pathophysiology of 
SCZ is hard to evaluate from genomic studies because a large number of neutral 
variants exist in the human genome, decrease the signal/noise ratio and prevent the 
true disease causing variants from being identified with sufficient statistical power. In 
addition, the genetic variation associated with mental disorders so far has largely 
been derived from genomic DNA using patients’ blood cells. Recently, evidence from 
various studies demonstrate that somatic mutations and mutations in the genes that 
control epigenetic mechanisms in affected brain regions could have important 
contribution to the etiology of neuropsychiatric disorders given the exuberant 
proliferation of cortical precursors during fetal development (Insel, 2014; Takata et al., 
2014; Tsankova et al., 2007).  
 
These observations led us to search for more effective approaches to enrich the 
potential rare disease causing variants. We reasoned that it would be more 














express in the affected brain regions and have altered expression pattern in SCZ 
patients. In addition, rare variants that are enriched in certain co-expression modules 
that contain the defect genes are more likely to contribute to the disease 
pathophysiology in the context of neurodevelopment. In this regard, recently 
developed RNA sequencing (RNA-seq) technique provides not only the greater linear 
range of detection or lower rates of false negatives and false positives than 
outperforms classical microarray data (Mortazavi et al., 2008; Wilhelm et al., 2008), 
but more importantly it provides single nucleotide resolution so that alterations in each 
expressed transcript can be unequivocally determined. Therefore, information carried 
by RNA-seq data at both genomic and transcriptional levels can be integrated to gain 
important insight into the contribution of rare protein-coding variants in the genetic 
architecture and related molecular pathophysiology of SCZ and isolate true causative 
variants with high penetrance from the irrelevant neutral variants.  
 
In this study, we developed such an integrated approach to analyze the RNA-seq 
data of the postmortem brain cingulate gyrus tissues from a set of well-characterized 
SCZ patients and matched controls (CO) and to explore the relationship between rare 
genetic variants and altered gene expression pattern in the context of 
neurodevelopment in SCZ patients (supplementary figure 1). The cingulate gyrus is 
an integral part of the limbic system involved in emotion formation and processing 
(Hadland et al., 2003) learning and memory (Sutherland et al., 1988). Its importance 
in psychiatric disorders (Drevets et al., 2008) is highlighted by abnormalities in 
cingulate gyrus volume (Costain et al., 2010; Takahashi et al., 2003), metabolism 
(Haznedar et al., 2004), connectivity (Wang et al., 2015) and astrocyte expression 
(Katsel et al., 2011) that have been repeatedly associated with the pathophysiology of 
SCZ. In this study, we utilized a gene expression analysis pipeline to determine the 
genes dysregulated in SCZ, and a variant detection pipeline in parallel to detect rare 
variation existing in expressed transcripts. We further evaluated the enrichment of 
rare variants to the genes that have altered expression pattern observed in the 
patients’ transcriptome (supplementary figure 1). Our analysis of relationship 
between variants distribution in different gene set categories pinpointed several 






Human brain tissue samples 
Human cingulate gyrus post-mortem samples from 31 SCZ patients and 26 healthy 
individuals were obtained from Stanley Medical Research Institute’s Array Collection 
database (http://www.stanleyresearch.org/brain-research/array-collection/). Main 
demographic characteristics are described in table1. Extended individual information 
by sample was also collected (supplementary table 1). SCZ Diagnoses were made 
using DSM-IV criteria. Neither significant difference in age nor in gender proportions 




















Age (years) (mean ± SD) 
a
 44.6 ± 7.1 42.4 ± 8.8 0.457 
 
Postmortem interval (hours) 
a








 22:4 23:8 0.516 
 
Duration of Illness - 21.8 + 10.1 - 
 
Lifetime dose of antipsychotics 
(g) 
c
 - 78.29 + 93.6 - 
 
 
   
 
 
Table 1. Demographic Characteristics of Control and Schizophrenia brain samples.  For p-
value calculations, Mann-Whitney (a) or two-tailed Fisher exact test (b) were used. Lifetime 
dose of antipsychotics are represented as fluphenazine equivalents (c). Bold values indicate 
significant P-values. 
 
RNA-seq data of postmortem brain samples of SCZ and CO  
RNA-seq data (raw fastq files) were obtained from the cingulate gyrus postmortem 
tissues of 31 SCZ patients and 26 healthy individuals. 75 bp pair-end sequencing was 
performed on Illumina Hiseq platform for both schizophrenic and unaffected sample 
set; two sequencing orphaned files were obtained for each sample analyzed (by default 
_1.fastq and _2.fastq). 
 
Differential expression analysis between SCZ and CO 
STAR aligner v2.3 (Dobin et al., 2013) was used to map reads from Illumina Genome 
Analyzer to the Human genome assembly hg19 following STAR 2-pass approach 
default parameters recommended by the Broad Institute RNA-seq best practices 
(https://software.broadinstitute.org/gatk/best-practices/). Output SAM files were first 
sorted with samtools v.1.2 (Li et al., 2009) and then imported into htseq-count, a tool 
developed in HTSeq package v 0.6.1 (Anders at al., 2014), to preprocess RNA-Seq 
data by counting the overlap of reads with genes. The whole counts vector files 
obtained for each sample were subsequently merged into a final matrix with the 
information of all read counts per gene and per sample. Gencode v19 comprehensive 
annotation file obtained from the UCSC Genome Browser was used to annotate the 
genes and isoforms. Overlapping isoforms of the same gene or different genes were 
merged into a unique locus using cufmerge tool from the cufflinks package (Trapnell et 
al., 2012). Throughout this paper, we used the term “genes” instead of “ loci” being 
aware that in some cases more than one gene is collapsed into the same unit. A total 
of 48099 genes were annotated, and gene counts were converted to RPKM values. We 
performed several filters to remove possible artifacts from our data. Firstly, genes with 
average reads per kilobase per million mapped reads (RPKM) < 0.3 in the whole 
expression dataset were removed as it was defined as a reliable cutoff to distinguish 
expression from noise (Ramsköld et al., 2009). This filter reduced the expressed 
dataset from 48099 to 22386 genes with detectable expression in our samples. 














not reaching RPKM > 0.3 cutoff in at least 90% of genes, and detected 2 SCZ and 9 
CO samples with marked low coverage (supplementary figure 3). PCA was then 
performed on the filtered expression dataset (22386 genes – all samples) to ensure low 
coverage samples were not separated from the rest (supplementary figure 4). Low 
and normal coverage samples are similarly distributed when representing PC1 vs PC2 
(both encompassing 84.2% of the variability). Indeed, a cross-validation procedure was 
also performed. Most variance (71.6%) was explained by first principal component 
(supplementary figure 4). Thus, eigenvalues vector for PC1 was then created 
excluding one different sample each time, and performing PCA on the remaining 
samples. Boxplot diagram was constructed to detect any potential outlier within 
eigenvalues distribution. No outlier was found across our data (supplementary figure 
5). Therefore, we did not exclude any sample for the gene expression analysis. 
The filtered raw gene counts were used by both EdgeR v.3.13.0 (Robinson et al., 2010) 
and DESeq v.1.22.0 (Anders et al., 2010) R packages to determine the differentially 
expressed (DE) genes between SCZ and CO. The overlapped genes with adjusted P 
values < 0.05 from both DESeq and EdgeR were used to generate a list of 1876 DE 
genes (supplementary figure 1). To ensure our method is robust, whole expression 
analysis was repeated removing the 2 SCZ and 9 CO samples with low coverage, 




Correlation analysis of gene expression pattern with lifetime medication 
exposure in the patient samples 
Influence of lifetime medication exposure on gene expression could be a confounding 
factor for clarifying the relationship between genetic variants and altered expression 
pattern due to the natural consequence of the disease. As the lifetime medication 
exposure was publicly available as part of samples information provided by Stanley 
Foundation, we calculated Pearson correlations between gene expression and lifetime 
medication for the 31 SCZ samples and 26 CO, for each of the 22386 genes with 
detectable expression (RPKM > 0.3). P values for each correlation were calculated 
using 500 bootstrap replicates relying on random sampling with replacement (Efron 
and Tibshirani, 1993).  
 
We used Benjamini-Yekutieli FDR (BY-FDR, Benjamini et al., 2001) procedure for 
multiple testing corrections for this correlation analysis, as this estimator 
is one improved from Benjamini-Hochberg FDR (BH-FDR, Benjamini et al., 1995) 
under some forms of dependence. We set, for a given gene, BY-FDR p-value > 0.05 as 
non-correlated with medication. In this study, we considered all genes with detectable 
expression (N=22386) and the subset of medication-independent genes (2104 genes 
with BY-FDR p-value > 0.05). Similarly, when only analyzing DE genes, we considered 
all DE genes (N=1876) and the subset of medication-independent DE genes (N=174). 
 
Gene Set Enrichment Analysis (GSEA) 
We performed GSEA (Subramanian et al., 2005) to check the enrichment in collected 
gene sets of co-expression modules recently published (Hawrylycz et al., 2012; Kang 
et al., 2011; Miller et al., 2014). Firstly, Kang et al. identified 29 co-expression modules 














distinct brain regions, mainly neocortical, spanning 15 periods from embryonic 
development to late adulthood (from 5.7 post-conceptual weeks (pcw) to 82 years old). 
Secondly, Hawrylycz et al. identified 13 co-expression modules (M1 to M13) from 
exhaustive transcriptomic study of two adult brains (24 and 39 years old) assaying 
more than three-hundred distinct structures at least once in both brains (Hawrylycz et 
al., 2012). Thirdly, Miller et al. identified 42 distinct modules from developmental 
transcriptome (C1 to C42) of four prenatal brains (two from 15 and 16 pcw and two 
from 21 pcw) across 25 areas of the developing neocortex. We also check the 
enrichment in cell-type enriched gene signatures from previous publications (Cahoy et 
al., 2008; Zhang et al., 2014). Brain cell-type specific signatures were defined by the 
genes whose expression levels are at least 1.5-fold higher in a specific cell type than 
the average of all other cell types (Zhang et al., 2014). We used cell type specific 
signatures derived from microarray data of developing and mature mouse forebrains 
(Cahoy et al., 2008), in which the significance was determined with a FDR p value < 
1%, and, subsequently, we confirmed our findings with the cell-type specific signatures 
derived from the RNA-seq analysis of mouse cerebral cortex (Zhang et al., 2014). For 
each test, expression dataset (N=22386) was used, a minimum of 10 genes were 
required for a given gene set to perform the GSEA analysis, 1000 permutations, 
weighted statistic enrichment and signal2noise metric were used for ranking genes. 
The default FDR adjusted p-values were used to assess enrichment significance. 
 
 
Cell-type Specific Expression Analysis (CSEA) 
We also analyzed cell-specific co-expression enrichment of DE genes with CSEA 
(Dougherty et al., 2010, Xu et al., 2014) using the available online tool 
(http://genetics.wustl.edu/jdlab/csea-tool-2/), which tests gene cell-type specific and 
spatiotemporal enrichment across development with Brainspan data 
(http://www.brainspan.org/). To test for association in any cell type of 
neurodevelopmental state, hypergeometric tests are performed, and the default BH-
FDR procedure is used to correct for multiple tests (Benjamini et al., 1995). We 
performed CSEA on DE genes up-regulated and down-regulated in SCZ, separately, 
as well as using medication-independent DE genes. 
 
 
RNA-seq variant identification pipeline 
Briefly, aligment of reads were carried out with GATK according to the best practices 
for variant calling on RNAseq, following by filtering of variants with low depth of 
coverage (DP<10), within unambiguously expressed genes (RPKM > 0.3) and MAF > 
0.01 in 1KG, ExAC or ESP. 
Specifically, raw alignment files were treated with Picard Tools 
(http://broadinstitute.github.io/picard/) version 1.109 to add read groups information, 
sort files, mark duplicated reads and index the output BAM file. These steps were done 
with both AddOrReplaceReadGroups.jar and MarkDuplicates.jar arguments. Marked 
BAM files were then subjected to a Genome Analysis Toolkit (GATK) pipeline 
(McKenna et al., 2010) according to the instruction of The GATK Best Practices for 
variant calling on RNAseq (http://gatkforums.broadinstitute.org/discussion/3892/the-
gatk-best-practices-for-variant-calling-on-rnaseq-in-full-detail). We applied an additional 














and necessary to correctly handle splice junctions. Next, split BAM files were subject to 
local realignment, base-score recalibration, and variant calling with the IndelRealigner, 
BaseRecalibration, and HaplotypeCaller tools from GATK. dbSNP138 and Mills and 
1000G gold standard indels databases were used as “known sites” to recalibrate 
quality values in every BAM files. HaplotypeCaller (HC) was used as variant calling 
algorithm instead of UnifiedGenotyper(UG), and recoverDanglingHeads and 
dontUseSoftClippedBases arguments were used to minimize false positive and false 
negative calls. The minimum Phred-scaled confidence threshold for calling variants 
was lowered from the default value 30 to 20, following the Broad Institute criteria for 
RNA-seq data. VCF files were obtained from the variant calling procedure and 
subsequently filtered on Fisher Strand values (FS > 30) and Quality by Depth values 
(QD < 2.0). (Supplementary figure 6).  
Next, to improve the quality of variant detection, we used a positional cutoff of minimum 
Depth of coverage (DP) in every sample to exclude the positions with lower depth of 
coverage, and only select those representing genomic positions expressed in all 
samples. Thus, we only preserved genome positions with at least ten reads (DP > 10) 
at that position in all samples. To achieve this goal, we used the Genomecov tool from 
Bedtools v 2.25.0 (Quinlan et al., 2014) to calculate coverage in processed BAM files. 
Gencode v19 comprehensive annotation merged with cufmerge was used, as in the 
expression analysis. Finally, IntersectBED program from Bedtools was used to extract 
the genes that satisfied our coverage cutoff criteria. Functional annotation of identified 
variants was performed with ANNOVAR (Wang et al., 2010) and AVIA tool (Vuong et 
al., 2015). As we focused on rare variants, all variants with a global frequency higher 
than 0.01 in any of three databases (1000 genomes phase 3 release (1KG), Exome 
sequencing project (ESP) v2 and Exome Aggregation Consortium v 0.3 (ExAC)) were 
removed. Moreover, as some of the detected variants could be RNA editing sites 
(RES) instead of real genomic variants, we interrogated two well-validated and recently 
published RNA editing databases, REDIportal (Picardi et al., 2016) and SPRINT 
(Zhang et al., 2017) to additionally filter detected variants. Both databases profiled RNA 
editing in human tissues, including brain samples. 
 
Variant-expression analyses 
In order to study variants in relation with expression profiles, only variation across 
genes with detectable expression (RPKM > 0.3) was gathered. As we noticed that 2 
SCZ and 9 CO had markedly less depth of coverage and do not pass sample cutoff 
(supplementary fig 5), but expression results were consistent after removing these 
samples, we studied genetic variants using filtered dataset of 29 SCZ and 17 CO. This 
way, despite reducing our sample size, we increased number of genomic positions 
reaching DP > 10 in every sample. We finally tested enrichment of rare singletons 
across co-expression modules significantly up or down-regulated in SCZ (Hawrylycz et 
al., 2012; Kang et al., 2011; Miller et al., 2014) (Supplementary Figure 6). For variant 
enrichment analyses, two-tailed Fisher exact test was performed between SCZ and CO 



















Differentially expressed genes in the cingulate gyrus region of the post-mortem 
brain tissues from the patients with SCZ 
We analyzed the differentially expressed gene pattern from the RNA-seq data of 57 
postmortem cingulate gyrus samples including 31 SCZ and 26 CO generated by the 
Stanley Research Foundation Array Collection (supplementary figure 1, see 
Methods). No potential sample outliers were found after performing a PCA cross-
validation procedure (Methods, supplementary figure 4). A total of 22386 Gencode 
genes (“whole genes”) showed detectable expression (RPKM > 0.3). From the whole 
gene set, 1876 were differentially expressed (“DE genes”) (FDR p < 0.05, see 
Methods). 1133 out of 1876 (60.4 %) genes had increased expression in patients 
compared to CO (“up-regulated DE genes”), while the remaining 743 (39.6 %) were 
down-regulated (“down-regulated DE genes”) in SCZ (supplementary table 2, 
supplementary figure 7).  
 
Given the demonstrated influence of medication throughout life in gene expression 
(Crespo-Facorro et al, 2015) in patients with SCZ, we also established Pearson 
correlations between gene expression levels and lifelong medication dosages in the 
patients (http://www.stanleyresearch.org/brain-research/array-collection/). Genes from 
“whole genes” were then classified as “medication-dependent genes or “medication-
independent genes” based on correlation significance values using BY-FDR threshold 
of 0.05. Of “All genes”, there are 2104 “medication-independent genes” and 20282 
“medication-dependent genes”. Interestingly, 174 of 2104 “medication-independent 
genes” were DE between SCZ and CO (“medication-independent DE genes”); of which 
79 were up-regulated and 95 down-regulated (“medication-independent up-regulated 
genes” and “medication-independent down-regulated genes”, respectively, 
supplementary table 3). We used independently “whole genes”, “medication-
independent genes” or “medication-dependent genes” as background in the GSEA 
analysis, while we focus on analyzing the corresponding DE genes for enrichment 
analyses henceforth throughout this manuscript. 
 
 
Medication-independent up-regulated genes are enriched in a co-expression 
module with astrocyte signature  
Taking into consideration the neurodevelopmental nature of SCZ (Najas-García et al., 
2014, Rapoport et al., 2012), we explored the enrichment of DE genes in various 
spatiotemporal co-expression modules previously defined in several transcriptome 
studies on developing human brain (Hawrylycz et al., 2012; Kang et al., 2011; Miller et 
al., 2014). Gene Set Expression Analysis (GSEA) is a well-established tool that is good 
at detecting small and cumulative effects in altered expression pattern (Subramanian et 
al., 2005). A total of 84 co-expression modules that were from three published studies 
and covered a series of embryonic development to late adulthood time periods and 
various distinct brain areas (see Methods) were used in our analysis. We first tested if 
there is any enrichment of the DE genes between SCZ and CO within these 84 distinct 
modules using whole genes (N=22386), medication-dependent genes (N= 20282), and 
medication-independent genes (N=2104) as background. 77, 68 and 35 modules 
passed size filters criteria for “whole genes”, “medication-dependent genes” and 
“medication-independent genes”, respectively and were used for GSEA analysis 














were significantly enriched in 5 modules including M10, C38, C36, K1 and K18; while 
“down-regulated genes” were enriched in 2 modules (M1 and K15) (FDR q<0.05, 
figure 1, table 2, supplementary table 5, supplementary figure 8-9). There are 
several modules such as the module C38, which was defined as an astrocyte gene set 
module (Cahoy et al., 2008); M10, with enrichment in astrocyte genes (Miller et al., 
2010); C36, with enrichment in astrocyte probable genes (Cahoy et al., 2008); In 
addition, module M1 is enriched in genes related to parvalbumin interneurons (Miller et 
al., 2010); module K1 is associated with cell cycle related functionality (Kang et al., 
2011), K15 is enriched in synaptic transmission functionality (Kang et al., 2011), and 
K18 is enriched in cell morphogenesis functionality (Kang et al., 2011). When only 
“medication-independent genes” background (N=2104) were considered, “medication-
independent up-regulated genes” were significantly enriched in only one module, C38 
from Miller et al (NC38=37; NES=1.92; BH-FDR-q=0.014, figure 1-2, table 2, 
supplementary figure 10). These results suggested that there is a significant 
enrichment of astrocyte signature in SCZ, which might be involved in the 
























        (A) All genes expressed (22386 




















upregulated 336 192 
1.83
4 
0.033 Cell cycle 
M10 
Hawrylyc
z et al. 









































Prenatal upregulated 628 384 
1.91
4 
0.049 Cell cycle 
        (B) Medication-independent genes expressed 




Prenatal upregulated 628 37 
1.92
2 
0.014 Cell cycle 
 
Table 2. Co-expression modules are enriched in the whole expression dataset (A) and the 
medication-independent expression dataset (B). Modules with significant enrichment after 
corrections for multiple tests (FDR-q < 0.05) are shown in the table. The original study they 
come from, brain type analyzed, status (downregulation/upregulation), genes expressed, 

















Figure 1. GSEA expression enrichment across spatiotemporal co-expression modules 
(Hawrylycz et al., 2012; Kang et al., 2011; Miller et al., 2014) within all genes with detectable 
expression (N = 22386), and medication-independent genes (N= 2104). Normalized enrichment 
score (NES) is represented in the figure, with negative NES values describing down-regulated 
modules in SCZ and positive NES values describing up-regulated modules in SCZ. Modules 
significantly enriched are marked in the figure (When hypergeometric test is significant FDRq-
val < 0.05 is marked with “*”, when FDRq-val < 0.1 is marked with “+”). All enrichment values, P 
values and numbers of genes are described in supplementary table 5A. Modules with less than 
















Figure 2. Heatmap of expression measures (RPKM) for the 37 genes that overlapped between 
module C38 (total # of genes = 628) and medication-independent gene set (total # of genes 
=2104). Expression measures from DESeq we used to compare RPKM values between 31 SCZ 
samples (left-grey colored) and 26 CO samples (right-yelow colored). 
 
In addition to PCA analysis and gene filtering (RPKM > 0.3) steps, to assess the 
robustness of our developed expression analysis methodology, we removed 9 CO and 
2 SCZ samples with low DP and repeated GSEA analyses to test enrichment of DE 
genes within co-expression modules using both whole genes (N=22386) and 
medication-independent genes (N=2104) as background. In both cases, we observed 
significant results similar to what happened in expression pipeline using all 
samples(supplementary table 6). Interestingly, when only medication-independent 
genes were considered, medication-independent up-regulated genes were again 
significantly enriched in C38 module from Miller et al (NC38=37; NES=1.80; BH-FDR-
q=0.038, supplementary table 6). Thus, we verified robustness of our methodology, 
and confirmed expression results do not depend on sample coverage differences.  
 
 
Cell-type Specific Expression Analysis shows alterations in cortical astrocyte 
signature in SCZ  
The finding that the “medication-independent genes” were enriched in an astrocyte 
related module promoted us to further investigate cell-type specific changes in our 














with GSEA tool using brain cell type signatures defined by previous experiments. We 
first analyzed enrichment using cell-type specific signature from one microarray data 
study (Cahoy et al., 2008). The cell-type specific GSEA analysis confirmed the 
“medication-independent up-regulated genes” were enriched in astrocyte signature 
defined by the microarray study (N=156 genes; NES=1.71; FDR q-val=0.037). 
Independently, we used the cell type signatures derived from an RNA-seq analysis of 
mouse cerebral cortex (Zhang et al., 2014) and further confirmed the enrichment 
astrocyte signature defined by the RNA-seq study under “medication-independent 
genes” background (N=279 genes; NES=1.8; FDR q-val=0.025; supplementary table 
7, supplementary figures 11-14).  
We confirmed this finding in a more systematic approach by utilizing the Cell-type 
Specific Expression Analysis (CSEA) tool, which are derived cell type signature using 
TRAP data (Xu et al., 2014). CSEA is an independent tool that based on 
experimentally affinity purification of the complete suite of translating mRNA from 
genetically labeled cell populations and a statistical integration of multiple specificity 
index probability (pSI) thresholds to determine overrepresentation of a putative list of 
genes in any given cell type and developmental state in central nervous system 
(Dougherty et al., 2010). As expected, the “medication-independent up-regulated 
genes” were significantly enriched in cortical astrocytes across several pSI thresholds 
(the lowest FDR q-val=8.01 x 10-4 at pSI threshold 0.01), and, less significantly in, 
cerebellum astrocytes (the lowest FDR q-val=0.035 at pSI threshold 0.01) and other 
glial cell types (the lowest FDR q-val=0.007at pSI threshold 0.05) (figure 3, 
supplementary table 8). This highly significant enrichment confirmed previous GSEA 
findings and suggested that alterations in astrocyte related genes were associated with 
the disease condition. In contrast, the “medication-independent down-regulated genes” 
were not found to be enriched in any specific cell types (supplementary figure 12, 















Figure 3. CSEA analysis reveals cortical astrocyte genes up-regulation beyond medication 
effects. The figure shows enrichments of up-regulated and medication-independent DE genes 
(N = 95) in specific cell types across brain using CSEA tool (BrainSpan data). Colored 
hexagons represent significant enrichments after FDR correction for hipergeometric test in 
different pSI thresholds. Enrichment values for every cell type are described in supplementary 
table 8. 
 
Genetic rare variation is overrepresented in genes from up-regulated astrocytic 
modules in SCZ 
We hypothesized that rare genetic variants (defined as allele frequency < 1% in 
general population) that are either within the genes with altered expression in affected 
brain regions of the patients or within the related co-expression networks are more 
likely to be enriched and the ones that contribute to the disease pathogenesis with high 
penetrance. Rare variants can be reliably identified from RNA-seq data for those genes 
with sufficient expression level (see Methods). Therefore, we conducted variant 
detection in the genes that are consistently expressed across all samples (DP>10 and 
RPKM > 0.3 in all samples, covering 1.35 Mb, which represents approximately 1.85% 
of GENCODE v19 exome). To ensure high quality in variant detection, we removed 2 
SCZ and 9 CO samples that had relatively low depth of coverage and did not passed 
sample filtering cutoff (supplementary figure 5). Importantly, when rerunning all gene 
expression analysis described above, significant findings hold even if these samples 















We also analyzed two well-validated databases that profiled RNA editing in human 
tissues including brain samples, REDIportal (Picardi et al., 2016) and SPRINT (Zhang 
et al., 2017), that comprised more than 4.5 million positions, to filter out variants 
described as potential RNA edits (RES). 6 and 2 variants affecting SCZ and CO 
samples, respectively, were removed based on this filter (supplementary table 9). 
Finally, variants with MAF > 0.01 in 1KG, ExAC or ESP were excluded. In total, we 
identified 796 rare SNVs and 131 indels in the transcriptomes of 29 SCZ and 17 CO 
(supplementary figure 6; Methods). These variants were within 623 genes. As 
expected, no global enrichment of rare variants was detected in the SCZ cases as 
compared to CO (SCZVar/Ind (CI 95%) = 20.00 ± 1.69, COVar/Ind (CI 95%) = 20.41 ± 2.49; 
t-test P-val = 0.771 supplementary table 10) due to existence of a large number of 
neutral variants.  
 
We further analyzed the rare variants within all genes in the altered modules identified 
in our expression analysis as they are more likely to be involved in the disease and 
therefore enriched. In our main expression analysis, we demonstrated that genes up-
regulated in SCZ are enriched in modules M10, C38, C36, K1 and K18, while genes 
down-regulated in SCZ are enriched in modules M1 and K15. Thus, we first analyzed 
variant enrichment in all genes within either the “up-regulated” or the “down-regulated” 
modules. Interestingly, we observed that rare singleton variants were more enriched 
(28 of 580 in SCZ versus 4 of 347 in CO; p = 0.0025, OR = 4.35, 95% CI = 1.50 – 
17.19; table 3) in genes from the upregulated modules including M10, C38, C36, K1 
and K18 (table 3). There are 28 rare singletons in cases, affecting 16 genes (N =29, 
0.96 variants/individual), and 4 singletons affecting 4 genes in controls (N= 17, 0.24 
variants/individual), reflecting a significant over-representation in SCZ versus CO 
(figure 4; Cochran-Armitage p = 0.0021; chi-sq = 9.48, df=1). No any enrichment was 
observed of these variants in genes from downregulated modules M1 and K15 (14 of 
586 in SCZ versus 12 of 349 in CO; p = 0.411, OR = 0.69, 95% CI = 0.29– 1.65; table 
3). We further analyzed rare variants in genes from medication-independent up-
regulated modules. There is only a module, C38 that contains significantly up-regulated 
and medication-independent genes. Interestingly, we detected 8 mutations across 
three genes (5 mutations in PCBD2, two in CAMTA1 and one in BCL2L14) in 29 SCZ 
and no mutations in 17 CO. The rare variants in this collection were significantly 




 Expression analysis Variant enrichment 












All genes  - - 623 580 347 0.98 - 
Genes overlap with Modules 
M1 – K15 Down-regulated Neuronal 20 14 12 0.69 0.412 
Genes overlap with Modules 
C38-C36-K1-K18-M10 Up-regulated Astrocyte 16 28 4 4.35 0.0025 
Medicate-independent genes 















Table 3. Variant enrichment in genes that belong to significantly up-regulated (C38, C36, 
K1, K18 and M10) and down-regulated modules (M1 - K15) from expression analysis 
across 29 schizophrenic and 17 control samples. Enrichment analysis was performed 
grouping downregulated modules and upregulated modules. Only genes with detectable 
expression (RPKM > 0.3) and genomic positions ubiquitously expressed (DP > 10) were 
considered. Among the genes mutated, ATP1A2 is present in M10 and C36 (1 variant), and 
LRIG1 is present in M10 and K18 (1 variant). The remaining genes did not overlap in any of the 
modules here analyzed (N=4 for M1; N=16 for K15; N=3 for C38; N=4 for C36; N=2 for K1; N=1 






Figure 4. Trend test result for variant accumulation in SCZ against CO. In the table and the 
lower histogram the number of mutations per individual is described, from the absence of them 







We further investigated the potential connection between rare variant enrichment in cell 
type specific signature using CSEA. Interestingly, we found that astrocyte signature 
genes that are up-regulated in SCZ carry more variants in SCZ than in CO (lowest FDR 
q-val=2 x 10-10 at pSI threshold 0.05 for Cerebellum astrocytes, supplementary figure 
15-16, supplementary table 12). These results further support a potential link between 





In this study, we analyzed the genetic makeup of the cingulate gyrus region from the 














CO at both transcriptome and genome levels. We demonstrated some interesting links 
between gene expression and genetic variants in an affected brain region. First of all, 
we found a total of 1876 DE genes in SCZ, of which 174 are DE independently of 
medication. Secondly, dissecting the properties of these DE genes using well-defined 
gene expression signature modules from various independent studies, we observed a 
significant enrichment of the DE genes in several co-expression modules previously 
identified in developing human brain tissues (Hawrylycz et al., 2012; Kang et al., 2011; 
Miller et al., 2014). Our further analysis on the cell type specific gene sets suggested 
that there is a consistent enrichment among the up-regulated gene set related to 
astrocytes and independent of medication administrated through lifetime. Of all the 84 
modules analyzed here by GSEA, prenatal co-expression module C38 (Miller et al., 
2014), highly enriched in genes with decreased expression with age and related with 
replication, cell proliferation and chromatin assembly, appeared to be significantly up-
regulated in SCZ in medication-independent expression dataset. Coherently with cell-
type analyses, module C38 is enriched in genes expressed mainly in astrocytes during 
prenatal development (supplementary information in Miller et al., 2014), highlighting the 
importance of this cell type and potential contribution to the pathophysiology of SCZ. 
During expression analysis, several quality filters regarding outlier detection, gene 
expression cutoff and sample coverage were applied, demonstrating high robustness 
of our results.  
  
Astrocytes are starting to be accepted to be equal important as neurons for normal 
neurodevelopment and function and malfunction of astrocytes can have a big impact 
on neuronal and higher cognitive functions observed in psychiatric disorders (Moraga-
Amaro et al., 2014). In fact, abnormalities in astrocytes have been repeatedly reported 
in psychiatric diseases. For example, altered gene expression in astrocytes was 
described in SCZ (Catts et al., 2104; Chandley et al., 2013; Bernstein et al., 2009; 
Bernstein et al., 2015). In addition, recent studies revealed strong abnormalities in 
astrocytes in SCZ, which in turn lead to a compensatory effect by which neurons 
overexpress excitatory amino-acid transporters (EAATs) due to a loss of expression of 
these transporters in astrocytes (McCullumsmith et al., 2015). In our study, astrocyte 
related genes appear to be up-regulated even in the medical-independent gene set, 
pointing out to a possible mechanism underlying the pathophysiology of SCZ instead of 
the medication effects, which could be possibly extensive to other neuropsychiatric 
conditions, as major depression (Rajkowska et al., 2013) or Alzheimer disease (Sekar 
et al., 2015). It also raises the possibilities that abnormalities in astrocytes could be a 
disease mechanism that is insensitive to medication interference.  
 
Furthermore, by investigating the rare variants within these altered co-expression 
modules and cell type specific gene sets, we found a significantly increase in the 
occurrence of rare variants in genes that belong to up-regulated and astrocyte-
signature modules. This observation agrees with our hypothesis that rare variants in 
the genes that are highly expressed in the affected brain regions are more likely to be 
associated with disease diagnosis. It is worth noting that although our sample size is 
quite small and has limited power, our result indicated the strategy to focus only in a 
subset of transcriptome regions covering highly and ubiquitously expressed genes 
could be a powerful way to pinpoint genetic variation contributing to expression 














be taken cautiously and suggestive, as larger sample sizes are needed to confirm 
these results. 
 
In addition, our study suggested several interesting candidate genes for further 
investigation: For example, INA, a gene that belongs to the third most associated locus 
in the most recent SCZ GWAS to date (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014) and clearly down-regulated in the patients 
with SCZ in this study (Fold change = 1.40; P-adj = 9.31 x 10-5), is the third most 
significant DE gene among the medication-independent dataset (supplementary table 
3). PCBD2, a gene that control BH4 metabolism and carries 4 rare mutations in SCZ 
but none in CO, also deserves further investigation. 
 
4 of the 5 mutations within PCBD2 are FMRP target sites for the most common form 
FMRPiso7 (Ascano et al., 2012), which is interesting regarding the reported implication 
of this target regions in SCZ (Fromer et al., 2014; Purcell et al., 2014, Kirov et al., 
2012) and in autism (De Rubeis et al., 2014). Although protein binding gene PCBD2 
has not been previously reported as a risk factor for neuropsychiatric conditions to our 
knowledge, this gene is involved in tetrahydrobiopterin (BH4) biosynthesis. BH4 is 
involved in the production of various neurotransmitters including serotonin, dopamine, 
epinephrine, and norepinephrine and is vital in nitric oxide (NO) production (Richardson 
et al., 2007; Werner et al., 2011). Deficiency in BH4 has been associated to SCZ 
(Richardson et al., 2005, Okusaga et al., 2014, Milstien and Katusic, 1999). In the likely 
context of astrocyte activation during early neurodevelopmental, post-transcriptionally 
regulatory mutations along PCBD2 could have an important role in BH4 synthesis and 
regeneration pathway, causing damaging disturbances in the mentioned processes. 
Further study of this pathway in the context of SCZ development is necessary to 
understand the biological insights of PCBD2 and involvement of BH4 pathway in SCZ. 
 
In relation to mutated genes from other co-expression modules, heterozygous 
intragenic rearrangements in CAMTA1, calmodulin-binding transcription activator 1, 
were associated with intellectual disability (ID) and cerebellar ataxia (Mikhail et al., 
2011; Thevenon et al., 2012) and deletion in this gene was also associated with autism 
(Pinto et al., 2010). Within genes from up-regulated module M10, glial fibrillary acidic 
protein GFAP, whose increased expression has been previously reported in SCZ 
(Catts et al., 2014) is mutated in 3 cases (1 exonic and 2 3'UTR mutations) but not in 
any CO. One of the UTR singleton variants, rs567636153, is a brain miRNA target site 
previously reported (Boudreau et al., 2014) and the individual with this variant has the 
higher expression value of the 46 individuals whose variants are studied, suggesting a 
likely genetic contribution of this UTR variant to the posttranscriptional regulation of this 
gene in a schizophrenic patient. Among the others genes mutated, other case has a 
variant (rs769452) in APOE rated as "probably damaging" in PolyPhen-2. This gene 
has been previously implicated in brain activity (Filippini et al., 2009) and extensively 
studied in SCZ with contradictory results (Martorell et al., 2008; Tovilla-Zarate et al., 
2009). Altered gene expression of PMP2, a peripheral myelin protein from the same 
family of PMP22, whose deletions at locus 17p12 are associated with SCZ (Rees et al., 
2013), has been previously reported in anterior cingulate cortex (Dracheva et al., 
2006). The neurotrophic tyrosine kinase receptor type 2 NTRK2 carries a mutation in 














with other risk genes (Lin et al., 2013) and related with miRNA target binding sites 




In summary, we have analyzed the transcriptome of patients with SCZ at both 
transcription and sequence level for the potential connection between altered gene 
expression pattern along the neurodevelopment and rare genetic variants within the 
expressed genes in an affected brain region. We consolidated the validity of 
neurodevelopmental model of SCZ making use of previously described co-expression 
modules and also in the context of rare genetic mutations, as had been indicated 
before (Gulsuner et al., 2013; Xu et al., 2011). Also, we found an interesting connection 
between up-regulated astrocytic gene sets and the enrichment of rare genetic variants 
that may potential contribute to differential gene expression in corresponding genes in 




CONFLICTS OF INTEREST 
The authors declaim no conflicts of interest. 
 
ACKNOWLEDGMENTS 
RNA-seq data from postmortem brain tissues was provided by The Stanley Medical 
Research Institute’s brain collection courtesy of Drs Michael B Knable, E Fuller Torrey, 
Maree J Webster, Serge Weis and Robert H Yolken. We thank Drs Joseph Gogos and 
Atsushi Takata for their valuable discussion of the analysis results. This work was 
partially supported by a National Alliance for Research in Schizophrenia and 
Depression (NARSAD) Young Investigator Award (to B.X.).  
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1KG: 1000 genomes phase 3 release 
BH-FDR: Benjamini-Hochberg False Discovery Rate 
BY-FDR: Benjamini-Yekutieli False Discovery Rate 
CNVs: Copy-number variants 
CO: Controls 
DE: Differentially expressed 
DP: Depth of coverage 
ESP: Exome sequencing project 














GSEA: Gene Set Enrichment Analysis 
NES: Normalized Enrichment Score 
pcw: Post-conceptual weeks 
RES: RNA editing site 
RNA-seq: RNA sequencing 
RPKM: Reads per kilobase per million mapped reads  
SCZ: Schizophrenia 
SNVs: Single nucleotide variant 
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 Co-expression modules with astrocyte signature are up-regulated in cingulate 
gyrus in schizophrenia. 
 Differences in gene expression in schizophrenia exist beyond influence of 
medication administrated.  
 Rare somatic variation affecting genes within co-expression modules with 
astrocyte signature are enriched in schizophrenia. 
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